REGENXBIO, Inc. (RGNX)
8.96
-0.24
(-2.61%)
USD |
NASDAQ |
Sep 04, 14:39
REGENXBIO Cash from Investing (Quarterly) : 65.92M for June 30, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 65.92M |
| March 31, 2026 | 70.59M |
| December 31, 2025 | 37.54M |
| September 30, 2025 | 42.29M |
| June 30, 2025 | -140.44M |
| March 31, 2025 | 44.74M |
| December 31, 2024 | 40.27M |
| September 30, 2024 | 50.26M |
| June 30, 2024 | -0.268M |
| March 31, 2024 | 13.18M |
| December 31, 2023 | 33.97M |
| September 30, 2023 | 38.66M |
| June 30, 2023 | 55.22M |
| March 31, 2023 | 63.09M |
| December 31, 2022 | 26.70M |
| September 30, 2022 | 53.04M |
| June 30, 2022 | -1.081M |
| March 31, 2022 | -90.59M |
| December 31, 2021 | -216.36M |
| September 30, 2021 | 16.10M |
| June 30, 2021 | 7.799M |
| March 31, 2021 | -214.18M |
| December 31, 2020 | 11.57M |
| September 30, 2020 | 34.00M |
| June 30, 2020 | 44.48M |
| Date | Value |
|---|---|
| March 31, 2020 | 32.71M |
| December 31, 2019 | 14.15M |
| September 30, 2019 | 52.27M |
| June 30, 2019 | 21.67M |
| March 31, 2019 | 5.461M |
| December 31, 2018 | -67.18M |
| September 30, 2018 | -136.72M |
| June 30, 2018 | -38.37M |
| March 31, 2018 | -37.09M |
| December 31, 2017 | -1.143M |
| September 30, 2017 | 18.76M |
| June 30, 2017 | -25.58M |
| March 31, 2017 | 3.163M |
| December 31, 2016 | 17.21M |
| September 30, 2016 | 9.799M |
| June 30, 2016 | 2.893M |
| March 31, 2016 | -10.74M |
| December 31, 2015 | -144.34M |
| September 30, 2015 | -19.14M |
| June 30, 2015 | -0.209M |
| March 31, 2015 | -0.106M |
| December 31, 2014 | |
| September 30, 2014 | |
| June 30, 2014 | |
| March 31, 2014 | 0.00 |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| AbbVie, Inc. | -1.197B |
| Capricor Therapeutics, Inc. | -48.76M |
| Biogen, Inc. | -3.839B |
| United Therapeutics Corp. | 87.50M |
| Ardelyx, Inc. | 22.66M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -62.24M |
| Cash from Financing (Quarterly) | 17.57M |
| Free Cash Flow | -249.67M |
| Free Cash Flow Per Share (Quarterly) | -1.188 |
| Free Cash Flow to Equity (Quarterly) | -65.06M |
| Free Cash Flow to Firm (Quarterly) | -55.20M |
| Free Cash Flow Yield | -53.36% |